Investment
Features
FeesSafety
Academy
More
Pluang+

Compare BioNano Genomics Inc (BNGO) vs DraftKings Inc (DKNG) Price & Performance

BioNano Genomics IncTrade
DraftKings IncTrade

Price performance (Past 24H)

Key statistics

BioNano Genomics Inc vs DraftKings Inc — how do they compare? BioNano Genomics Inc trades at $1.18 (market cap $13.66M), while DraftKings Inc trades at $25.41 (market cap $12.58B). The key difference: DraftKings Inc is far larger — about 920.9× BioNano Genomics Inc's market cap, and DraftKings Inc is trading nearer its 52-week high, BioNano Genomics Inc nearer its low. Which is the better fit depends on your goals.

BNGODKNG
Market Cap
$13.66M$12.58B
Sector
HealthConsumer Cyclical
52-Week High
$4.92$48.23
52-Week Low
$1.06$20.72
Enterprise Value
$16.26M$13.51B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

BioNano Genomics Inc

BNGO trades at $1.195, up 3.02% today, with a bullish technical signal from moving averages but a neutral oscillator stance. The company shows improving financial trends, with net losses narrowing to -$26.40M in 2025 from -$232M in 2023, and recent earnings beats. Revenue stabilized around $29M, while cash flow trends indicate reduced operational cash burn. Analyst sentiment is positive, with 57% buy ratings.

The outlook for BNGO hinges on sustaining revenue growth and achieving profitability, supported by strategic hires and debt retirement. Key risks include persistent negative margins and high cash burn. With a low P/S of 0.31, the stock offers value if execution improves, but investors face volatility from operational challenges and competitive pressures.

DraftKings Inc

DraftKings (DKNG) trades at $25.79, up 6.24% on the day, with a bullish technical signal and strong analyst consensus. Revenue grew to $6.05 billion in 2025, though recent quarters show earnings misses. The company is expanding into prediction markets, with CEO Jason Robins highlighting rapid growth ahead of the NFL season (Bloomberg Technology, 2026-08-07).

The outlook is mixed: strong revenue growth and positive cash flow from operations contrast with high valuation multiples and recent profitability challenges. Key risks include competition from prediction markets and promotional costs pressuring margins. The consensus price target of $34.00 suggests upside potential if execution improves.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About BioNano Genomics Inc

Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes.

Read more on BNGO

About DraftKings Inc

DraftKings Inc is a digital sports entertainment and gaming company. The company provides users with daily fantasy sports (DFS), sports betting, and iGaming opportunities and is also involved in the design & development of sports betting and casino gaming platform software for online and retail sportsbook and casino gaming products. It operates in two segments: Business-to-consumer(B2C) and Business-to-Business(B2B), of which the vast majority of its revenue comes from the B2C segment. Geographically, it derives most of its revenue from the United States.

Read more on DKNG